Compare NDLS & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NDLS | TENX |
|---|---|---|
| Founded | 1995 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 71.1M |
| IPO Year | 2013 | 2001 |
| Metric | NDLS | TENX |
|---|---|---|
| Price | $13.74 | $1.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 26.2K | ★ 7.0M |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $495,089,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.37 | N/A |
| 52 Week Low | $0.47 | $1.31 |
| 52 Week High | $19.00 | $19.40 |
| Indicator | NDLS | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 42.95 | 26.18 |
| Support Level | $12.83 | $1.31 |
| Resistance Level | $16.10 | $2.43 |
| Average True Range (ATR) | 0.86 | 0.19 |
| MACD | -0.15 | 0.47 |
| Stochastic Oscillator | 15.92 | 37.11 |
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.